Adding HR photos ...

Net Sales from Continuing Operations Were a Fourth Quarter and Fiscal Year Record Delivered Fiscal Year 2023 Double-Digit Improvement in Gross Profit, Operating Income and EPS, Year-Over-Year  Achieved Sixth Consecutive Quarter of Year-Over-Year Gross Margin Expansion Launching 'Project Energize' Investment and Efficiency Program to Drive the Company's One Perrigo Sustainable, Value Accretive Growth Strategy  DUBLIN, Feb. 27, 2024 /PRNewswire/ -- Fourth Quarter 2023 Highlights: Fourth quarter net sales of ...

DUBLIN, Feb. 26, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, announces that its Board of Directors has approved a 1% increase in the Company's quarterly dividend to $0.276 per share, or $1.10 per share on an annual basis, up from $0.273 per share. This marks the 21st consecutive year Perrigo has increased its dividend. The cash dividend is payable on March 26, 2024, to shareholders of record on March 8, 2024. About Perrigo  Perrigo Company ...

EXHIBIT 99.1 Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program Net Sales from Continuing Operations Were a Fourth Quarter and Fiscal Year Record Delivered Fiscal Year 2023 Double-Digit Improvement in Gross Profit, Operating Income and EPS, Year-Over-Year Achieved Sixth Consecutive Quarter of Year-Over-Year Gross Margin Expansion Launching 'Project Energize' Investment and Efficiency Program to Drive the Company's One Perr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-36353 Perrigo Company plc (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or or ...

DUBLIN, Feb. 13, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2023 financial results on Tuesday, February 27th, 2024 and will host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or b ...

Financial Data and Key Metrics Changes - The company reported net sales growth of 2.2% year-over-year, while organic net sales declined by 1.2% due to the impact of discontinued lower margin SKUs [6][20] - Gross margin expanded by 300 basis points to 39.5%, and operating margin increased by 130 basis points to 13.4% [6][22] - Adjusted diluted earnings per share (EPS) was $0.64, up from $0.56 in the prior quarter, reflecting a year-over-year growth of 14.3% [20][22] Business Line Data and Key Metrics Changes - In the global cough, cold, and pain products segment, net sales increased by 7% year-over-year, driven by strong seasonal selling, particularly in Europe [7] - CSCI (Consumer Self-Care International) saw organic net sales grow by 6.2%, while CSCA (Consumer Self-Care Americas) experienced a decline of 5.1% due to various factors including the discontinuation of low margin SKUs [7][8] - The infant formula segment faced challenges due to updated FDA guidelines, impacting production and safety stock levels [9][25] Market Data and Key Metrics Changes - Store-brand OTC dollar, volume, and value share grew over the last 13 weeks, indicating a consumer shift towards high-quality, value products [8] - The company anticipates continued market share gains in the Americas while focusing on rebuilding safety stock in the infant formula category [17] Company Strategy and Development Direction - The company aims to build a sustainable and value-accretive growth engine through four key pillars: consumerization and digitization, category growth partnerships, leveraging global supply chain, and optimizing a global operating model [12][14] - The anticipated launch of Opill is expected to create a new OTC category in the U.S., with a focus on innovative marketing strategies to drive consumer engagement [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and highlighted the unique market position with a $400 billion addressable market in the global self-care segment [12][13] - The company expects to normalize operations in the infant formula segment by mid-2024 and recapture most of the EPS impact from lower sales [30][25] Other Important Information - The company is working to address the impact of recent FDA guidelines on production and inventory management, which has led to lower customer in-stocks and lost sales [9][25] - The company reaffirmed its commitment to reducing net leverage, targeting around three times net debt to adjusted EBITDA by the end of 2025 [24] Q&A Session Summary Question: Impact of lower infant formula sales on 2023 guidance - Management indicated a $0.35 EPS impact from lower infant formula sales, with expectations to recapture this by mid-2024 as production normalizes [30] Question: Expected gross margin progression - Management expects to exceed the previously mentioned 200 basis points improvement in gross margin due to strategic pricing and portfolio optimization [32] Question: Store brand versus national brand share gains - Management confirmed a 0.7% volume share gain for store brands across categories, with positive trends continuing into October [36] Question: Price increases and consumer response - The company implemented nearly a 5% price increase, primarily in the infant formula segment, without significant pushback from retailers [41] Question: Production changes for phenylephrine products - Management noted that phenylephrine products account for only 2% of total net sales, with minimal impact expected from recent FDA discussions [45] Question: Response to SKU rationalization efforts - Management reported positive feedback from retailers regarding SKU rationalization, which has simplified operations and improved value creation [49][50] Question: Launch of Opill and its financial impact - The launch of Opill is expected to be dilutive in 2024, but management remains optimistic about maintaining EPS growth in the range of $2.90 to $3 [55]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q _______________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36353 Perrigo Company plc (Exact name ...

Adding HR photos ...

Perrigo Company plc (NYSE:PRGO) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Patrick Taylor - President and Chief Executive Officer Eduardo Bezerra - Executive Vice President and Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Alec Legg - Canaccord Genuity Daniel Biolsi - Hedgeye Operator Good Day and welcome to the Perrigo Second Quarter 2023 Financial Results Conference Call. All participants w ...